Articles tagged with Chemotherapy
Researchers at Wayne State University have developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs to reverse drug-resistance in renal cell carcinoma. The technology uses tumor hypoxia-directed nanoparticles to target the root cause of the problem and has shown promising results in animal trials.
Scientists have discovered a way to enhance the effectiveness of artemisinin, a powerful antimalarial drug, by combining it with chemotherapy medicines that target the parasite's waste disposal system. The combination works by jamming the recycling process, leading to cell death in the parasite.
Scientists have demonstrated that adding aluminium atoms to active carbon delivery capsules increases the adsorption of chemotherapy drugs, like 5-Fluorouracil, onto targeted delivery devices. This could lead to more effective cancer treatments with fewer side effects by encapsulating chemo drugs into active carbon.
Researchers at University of Houston develop synthetic compound that inhibits two major pathways of pancreatic cancer. The drug, MA242, targets NFAT1 and MDM2, reducing tumor growth and progression.
Researchers at McMaster University have identified a previously unknown cell population that triggers the return of acute myeloid leukemia after remission. This discovery provides a potential new target for therapies and offers hope for improving treatment outcomes for patients with leukemia.
Skin cells can detect damaged DNA in the absence of infection and trigger an immune response similar to that observed during viral infections. This discovery could lead to new cancer treatments and preventive measures against skin cancers.
A Moffitt Cancer Center research team compared chemotherapy regimens and found that a combination called ddMVAC was associated with higher complete response rates and improved survival rates compared to standard care. The study analyzed data from over 800 surgical patients with advanced bladder cancer.
A study published in the Journal of the American Geriatrics Society found that short-term decline in physical function was common among older adults treated with chemotherapy for breast cancer. However, about half of patients were resilient and able to recover their ability to function within 12 months.
UTEP scientists have received a $6 million grant from the National Institutes of Health to develop new regimens and biomarkers for Chagas disease treatment. The researchers aim to improve the efficacy and safety of current treatments, which are toxic and have low effectiveness.
Scientists at Salk Institute and Purdue University discovered a key to mass-producing beneficial plant compounds, including terpenoids used in fragrances, flavorings, biofuels, and pharmaceuticals. They found that plants have an
Researchers at Washington State University discovered that cancer-fighting drugs can slow or stop fungal infections in plants by activating genes used to defend against pathogens. The study showed two different results from the applications of DNA-specific drugs on pea tissue, with differing mechanisms of action.
Researchers at University of Illinois Chicago discovered that a mutation in the NPM1 gene helps improve sensitivity to chemotherapy in patients. The study found that patients with this mutation tend to respond better to chemotherapy and have higher rates of remission.
Researchers developed a novel polymer conjugate to deliver anticancer drugs directly to cancer stem cells, significantly reducing tumor size. The combined use of standard anticancer drugs further enhanced the effect.
Researchers have discovered that antibodies in mother's milk can survive the digestive system and deliver intact molecules into a baby's bloodstream. Now, they hope to encapsulate chemotherapy drugs in milk particles to create a potential alternative to infusions.
A recent study found that 8.3% of trastuzumab-treated patients developed heart failure, highlighting the need for cardiac monitoring in high-risk breast cancer patients. The study also showed a consistent increase in heart failure risk with age, emphasizing the importance of prioritizing cardiac monitoring for younger patients.
Researchers found that doxorubicin targets enzymes controlling immune responses in the spleen and heart, disrupting metabolism and leading to impaired inflammation resolution. The drug also poisons specific immune cells, causing a loss of host defense and promoting chronic non-resolving inflammation.
The study identified four fungi species with high anti-cancer potential, including polyphenols, polysaccharides, and terpenoids. These compounds show selective targeting of malignant tumors with minimal harm to healthy cells.
Chemists at the University of Basel have developed a novel synthesis method for terpenes that uses molecular capsules to mimic nature. The method significantly reduces the number of steps and improves yield in the synthesis process.
A new study found that Cannabidiol (CBD) significantly improved the survival rate of mice with pancreatic cancer when used alongside chemotherapy. The treatment resulted in nearly tripled survival time compared to those receiving chemotherapy alone.
Research published in eNeuro suggests that cannabidiol can prevent nausea in rats by increasing serotonin levels in the brain. The findings implicate the endocannabinoid system and its role in regulating nausea, opening up new therapeutic opportunities.
Researchers have developed a novel delivery system using magnetic nanoparticles to target chemotherapy drugs to spinal cord tumors, which are difficult to reach due to the blood-brain barrier. This approach shows promise in treating intramedullary spinal cord tumors with improved survival rates and reduced side effects.
Researchers at the University of Illinois Chicago developed a magnetic surgical cement that can guide nanoparticles to lesions near spinal fractures, providing targeted drug delivery. The technology has the potential to become a surgical option for patients with primary spinal column tumors or metastasizing tumors.
Australian researchers found that follistatin, a naturally occurring hormone, can enhance the effectiveness of platinum-based chemotherapy and prevent kidney damage in lung cancer patients. The 'two birds, one stone' approach has shown promising results in mouse models.
Researchers developed a method to create 3D cultures of clustered cancer cells that better mimic tumors, enabling more accurate drug testing. A new NIH grant will model the response of colon cancer cells to anticancer drugs, aiming to identify molecular mechanisms of drug resistance and develop new treatment strategies.
Researchers developed a technique to measure drug-target engagement in individual cancer cells, revealing variation in effectiveness between cells within a tumour. The findings could help clinicians choose the best course and delivery of treatment for cancer patients, improving treatment outcomes.
Researchers developed an algorithm that combines genomic information to predict individual responses to anticancer drugs. The new tool, pGENMi, uses gene expression, DNA sequence and epigenetic factors to identify key characteristics associated with specific drug responses.
A study published in Science Translational Medicine found that acetazolamide increases sensitivity to treatment and enhances survival in mice with glioblastoma. The drug, which is also used to treat altitude sickness, was able to restore the effectiveness of chemotherapy by blocking a protein called BCL-3.
A study published in Antimicrobial Agents and Chemotherapy found that nearly half of all prescriptions reviewed were prescribed unnecessarily, with a third of cases involving non-face-to-face encounters. The research highlights the need for improved antibiotic stewardship in outpatient clinics.
The California Institute for Regenerative Medicine (CIRM) has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy. The trial is expected to star...
Macrophage receptors trigger intestinal contractions, leading to severe diarrhea in cancer patients undergoing chemotherapy. The discovery opens up new avenues for developing targeted treatments for this debilitating side effect.
Scientists at Scripps Research have discovered a previously unknown mechanism by which bacteria protect themselves from toxic substances, providing new clues for improving chemotherapies. The study reveals that three genes encode proteins that bind to toxins, keeping them separate from the rest of the organism.
Researchers found that PARP inhibitors, such as rucaparib, showed promise in treating pancreatic cancer in patients with BRCA mutations. In a small study, 32% of patients experienced disease control after treatment.
A Phase II study found that over half of women with early-stage BRCA+ breast cancer who took talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. The oral medication showed high response rates and manageable toxicities, offering an alternative to chemotherapy for this patient population.
A landmark study published in the New England Journal of Medicine found that most breast cancer patients with intermediate scores on a 21-gene test can safely avoid chemotherapy. The study's results have significant implications for doctors and patients, allowing for more personalized treatment options.
A new trial presented at ASCO18 shows that PET scans can improve treatment outcomes for esophageal cancer patients. Patients who responded to induction chemotherapy had a median overall survival of 46 months, while those who did not respond had a 27-month median survival, significantly better than previous studies.
According to a new analysis of over 8,000 patients, African-American men with advanced prostate cancer who received docetaxel-based therapies had a lower risk of death than white men. This finding is significant, as it challenges the long-held notion that racial disparities in prostate cancer survival are due to biological differences.
Researchers discovered a naturally occurring protein called apolipoprotein A-I binding protein (AIBP) that inhibits inflammatory response underlying chronic pain processing. A single spinal injection of AIBP alleviated chemotherapy pain in mice for two months with no side effects.
Children with leukemia experience frequent vertebral fractures during chemotherapy, often persisting into adulthood. Vertebral deformities are more common in older children and those with severe collapse.
A small study of adults with pancreatic cancer reveals that patients with BRCA1 or BRCA2 gene mutations have poorer overall survival rates compared to those without the mutations. However, those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy.
Researchers have developed new treatment regimens that significantly boost survival rates for children and young adults with rare forms of leukemia and lymphoma, such as T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). The trial showed that 90% of patients lived at least four years after starting tre...
Cancer cells express specific sugar receptors that can be targeted for better drug delivery. Researchers are developing nanocarrier formulations to accumulate in tumor sites and minimize side effects.
A clinical trial conducted by Boston Children's Hospital has shown that adding chemotherapy to a treatment regimen including catheterization and surgery can deter abnormal cellular growth in children with pulmonary vein stenosis. The approach led to the stabilization of PVS progression and prevention of further lung damage in 31% of pa...
Researchers have found a novel therapeutic that interrupts signaling cascades in the body required for multiple forms of neuropathic pain. The treatment targets the nNOS-NOS1AP protein-protein interactions, reducing neuropathic pain in rodents and disrupting nociceptive signaling.
A targeted 'click-to-release' chemotherapy approach has shown promising results in mice, demonstrating effective anticancer effects against ovarian and colon cancers. The innovative method, developed by Tagworks Pharmaceuticals, releases a large quantity of chemotherapy drug quickly, attacking the tumor cells.
A WSU research team has made a breakthrough in 3D-printed bone health by combining natural medical cures with modern biomedical devices. The addition of curcumin to ceramic scaffolds improved bone growth capabilities by 30-45%, offering new hope for treating bone diseases like osteoporosis.
A new study presented at the AATS Annual Meeting shows that patients with malignant lymph nodes following preoperative therapy were less likely to survive than those with no cancer. The study found a strong association between pathologic nodal response and improved survival, highlighting the need for optimized neoadjuvant strategies.
Researchers discovered that a multiple sclerosis drug can mitigate the painful side effect of cancer treatment bortezomib. Fingolimod, an approved multiple sclerosis medication, blocks the production of molecules causing nerve damage and alleviates neuropathic pain.
Researchers found that blocking tumor-associated macrophages can improve chemotherapy response in neuroblastoma, even in T cell deficient mice. This new approach may be effective for children with high-risk disease and could lead to the development of new combination therapies.
Researchers have made significant breakthroughs in treating pancreatic, colon and breast cancers, as well as developing new pain treatments for chemotherapy-induced peripheral neuropathy. A new compound has shown promise in targeting cancer cell death pathways, while indomethacin has been found to inhibit colon cancer growth.
Researchers discovered that pre-existing chemoresistant genotypes in tumors can adapt to become fully resistant to chemotherapy, leading to poor overall survival. The study's findings may lead to diagnostic opportunities for detecting resistant clones in TNBC patients before treatment.
Researchers developed a nanodisc delivery system that combines chemotherapy with immune checkpoint blockers to eliminate tumors in 85% of treated mice. The therapy also showed an excellent response rate of 88% in a challenging model, and no overt side effects were detected.
Researchers have systematically mapped connections between 625 breast and ovarian cancer genes and nearly every FDA-approved chemotherapy for these cancers. The map reveals new genetic factors that determine the response of tumor cells to common classes of chemotherapy treatment.
Combination therapy of pembrolizumab and chemotherapy significantly improves overall survival and reduces progression risk in patients with non-squamous non-small cell lung cancer. The study found a 51% reduced risk of death compared to chemotherapy alone.
A new liquid biopsy-based cancer model has revealed insights into the development of chemotherapy resistance in small-cell lung cancer. The study found that intratumoral heterogeneity, or differences in gene expression between tumor cells, contributes to rapid chemotherapy resistance.
Researchers identified PDE5 inhibitors, like Viagra, as potential treatments for glioblastoma multiforme and other rare cancers. The study suggests these drugs may increase permeability to improve drug delivery to brain tumors.
Researchers found that simultaneous chemotherapy and immunotherapy is safe and patients with certain genetic mutations may respond particularly well. The combination approach was shown to boost immune cells in the blood, allaying previous concerns about chemotherapy's impact on immunotherapy.
A new NCI study revises molecular classification for diffuse large B-cell lymphoma, identifying four prominent genetic subtypes that can help explain treatment response. The study's findings will aid in predicting prognosis and tailoring therapy for patients with DLBCL.
A study by researchers at the National University of Singapore found that almost half of breast cancer patients experience cognitive decline during treatment, with symptoms persisting up to a year after. The study highlights the importance of early screening and management to improve quality of life for survivors.
A new biomarker identified a 'window of opportunity' for cancer chemotherapy timing, optimizing the effectiveness of anti-angiogenic and anticancer drug combinations. The biomarker, CD109 expression in vascular endothelial cells, correlates with tumor cell growth and enables the visualization of proliferating blood vessels.
Seven new grants will support studies on personalized treatments, non-invasive cancer cell killing, and early tumor detection using advanced imaging techniques. These projects aim to improve survival statistics for pancreatic cancer patients and accelerate research progress.